Technology Opportunities

Novel treatment for Parkinson’s disease overcomes “on-off” phenomenon

Highlights

• Increases the endogenous level of dopamine to alleviate the motor complications of Parkinson’s disease and to delay the onset of the symptoms from the dramatic decrease in dopamine
• Formulated for buccal, oral, sub-lingual, parenteral, intranasal, intramuscular, intravenous, subcutaneous, intraduodenal or rectal administration

Our Innovation

• Provides a pharmaceutical preparation for the treatment of patients suffering from PD comprising a composition of L-Dopamide
• A water-soluble compound could be applied f for rescue therapy. An advantage over the insoluble L-DOPA
• Involves an essential structural change to make L-DOPA more soluble and resistant to DOPA Decarboxylase
• Administrable without Carbidopa due to resistance to DOPA-decarboxylase
• L-Dopamide is slowly hydrolyzed to L-DOPA because it is resistance to DOPA decarboxylase
• Slow release addresses the on/off phenomenon of Parkinson’s
• Degrades to natural products

The Opportunity

Addresses the need for more effective therapy for Parkinson’s disease using a more sustained level of dopamine

Oral results

Oral application in animal model showed longer duration > 40% over L- DOPA.

• Higher efficiency as a proof of concept in experiments made side by side with L-DOPA
• PK studies available

Development Milestones

Ready for toxicology studies.